OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
6639$1.8358

Arrail Group Ltd

Healthcare Facilities & ServicesVerified

Arrail Group Ltd has a market capitalization of CNY 1.03 billion, with a current market price of CNY 1.83 per share. The company has no dilution risk, as the number of basic and diluted shares outstanding is identical at 562,095,450. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability and return metrics are not available for Arrail Group Ltd, as the valuation snapshot does not include key financial ratios such as ROIC or margins. Analysts have provided a mean price target of CNY 3.18, with a median and high target also at CNY 3.18, indicating a consensus on the stock's potential upside. The mean recommendation score is 2.00, suggesting a generally positive outlook, although no strong buy ratings have been issued. The company's revenue concentration and geographic exposure are not disclosed in the available data. There is no information on specific segments or geographic regions contributing to revenue, which limits the ability to assess diversification risk. Growth trajectory is not quantified in the available data, as no revenue history or outlook numeric deltas are provided. Analysts have not issued any growth-related guidance, and the company's future performance remains speculative. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data. No dilution risk is currently present, as the number of basic and diluted shares is the same. However, the absence of going-concern language in source documents raises concerns about the company's financial health. Recent events, including filings and transcripts, are not disclosed in the available data. There is no information on recent corporate actions, earnings calls, or regulatory updates that could impact the company's valuation or operations.

30-day price · 6639+0.00 (+0.0%)
Low$1.83High$1.83Close$1.83As of21 May, 00:00 UTC
Profile
CompanyArrail Group Ltd
Ticker6639.HK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Arrail Group Ltd is a biotechnology company that provides healthcare facilities and services, primarily generating revenue through its operations in the healthcare sector.

Classification. Arrail Group Ltd is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a classification confidence of 0.92.

Arrail Group Ltd has a market capitalization of CNY 1.03 billion, with a current market price of CNY 1.83 per share. The company has no dilution risk, as the number of basic and diluted shares outstanding is identical at 562,095,450. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. Profitability and return metrics are not available for Arrail Group Ltd, as the valuation snapshot does not include key financial ratios such as ROIC or margins. Analysts have provided a mean price target of CNY 3.18, with a median and high target also at CNY 3.18, indicating a consensus on the stock's potential upside. The mean recommendation score is 2.00, suggesting a generally positive outlook, although no strong buy ratings have been issued. The company's revenue concentration and geographic exposure are not disclosed in the available data. There is no information on specific segments or geographic regions contributing to revenue, which limits the ability to assess diversification risk. Growth trajectory is not quantified in the available data, as no revenue history or outlook numeric deltas are provided. Analysts have not issued any growth-related guidance, and the company's future performance remains speculative. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data. No dilution risk is currently present, as the number of basic and diluted shares is the same. However, the absence of going-concern language in source documents raises concerns about the company's financial health. Recent events, including filings and transcripts, are not disclosed in the available data. There is no information on recent corporate actions, earnings calls, or regulatory updates that could impact the company's valuation or operations.
Key takeaways
  • Analysts have issued a consensus price target of CNY 3.18, indicating a potential upside from the current market price of CNY 1.83.
  • The company has no dilution risk, as the number of basic and diluted shares is identical.
  • Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
  • No revenue concentration or geographic exposure data is available, limiting the ability to assess diversification risk.
  • Growth trajectory and future performance remain speculative due to the absence of revenue history and outlook numeric deltas.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$1.52B-$72.2M-$599.4M-$398.6M
FY-3$1.62B-$28.6M-$701.0M-$570.8M
FY-2$1.47B-$190.3M-$219.9M-$74.7M
FY-1$1.75B$26.0M$17.2M$179.7M
FY0$1.69B$36.2M$22.0M$204.9M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$2.35B-$2.50B$373.1M
FY-3$2.99B$1.56B$238.4M
FY-2$3.06B$1.61B$384.1M
FY-1$3.25B$1.76B$390.7M
FY0$3.16B$1.71B$105.9M
PeriodOCFCapExFCFSBC
FY-4$242.9M-$29.8M-$398.6M
FY-3$224.3M-$120.7M-$570.8M
FY-2$131.7M-$112.8M-$74.7M
FY-1$276.7M-$92.4M$179.7M
FY0$231.1M-$58.5M$204.9M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price$1.83
Market cap$1.03B
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
Metric6639Activity
Op margin5.6% medp25 -4.2% · p75 12.6%
Net margin2.8% medp25 -3.4% · p75 8.8%
Gross margin36.5% medp25 23.7% · p75 65.2%
CapEx / revenue-4.9% medp25 -11.5% · p75 -2.0%
Debt / equity69.3% medp25 7.9% · p75 120.9%
Observations
IR observations
Mean price target3.18 CNY
Median price target3.18 CNY
High price target3.18 CNY
Low price target3.18 CNY
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EBIT estimate24,900,000 CNY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-11 00:04 UTC#b81d4237
Market quoteclose CNY 1.83 · shares 0.56B diluted
no public URL
2026-05-11 00:04 UTC#d45f9448
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 01:57 UTCJob: 1bcdae3a